<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043701</url>
  </required_header>
  <id_info>
    <org_study_id>ISM-GBM</org_study_id>
    <nct_id>NCT05043701</nct_id>
  </id_info>
  <brief_title>Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma</brief_title>
  <acronym>ISM-GBM</acronym>
  <official_title>Individualized Systems Medicine Strategy for Targeting Cancer Stem Cells in Patients With Recurrent Glioblastoma (ISM-GBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute for Molecular Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to determine the feasibility and safety of individualized cancer stem cell targeted&#xD;
      therapy based on high-throughput functional profiling of FDA/EMA-approved drugs in patients&#xD;
      with GBM that has recurred or progressed following standards-of-care (RT, TMZ).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol describes a prospective single-center phase 1 study to evaluate the feasibility&#xD;
      and safety of a high-throughput drug sensitivity and resistance testing (HTS) platform of&#xD;
      individualized cancer stem cells (CSC) to predict targeted therapies in patients with&#xD;
      recurrence of GBM after standards-of-care. Secondary outcome include efficacy of drug&#xD;
      treatment. The underlying hypotheses is that treatment of patients based on functional&#xD;
      profiling og autologous CSCs using HTS a) is feasible within an acceptable time window for&#xD;
      clinical translation, b) safely delay disease progression and c) increase survival. There are&#xD;
      increasingly published literature that strongly support the importance of a targeting CSC to&#xD;
      improve therapy and prevent tumor recurrence in GBM, as an additional strategy to improve the&#xD;
      overall prognosis of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open labelled intervention study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug screen completion and treatment initiation</measure>
    <time_frame>8 weeks after surgery</time_frame>
    <description>The fraction of patient that can receive an individualized treatment based on drug screening. These drugs must be available for treatment and with a combined acceptable toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>15 months from inclusion</time_frame>
    <description>Tumor response by the chosen drug combination evaluated according to the updated response assessment in neuro-oncology (RANO) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of grade 3-5 adverse events</measure>
    <time_frame>15 months from inclusion</time_frame>
    <description>Adverse events induced by selected treatments according to NCI Common Terminology Criteria for Adverse Events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>15 months from inclusion</time_frame>
    <description>Overall survival in treated patients from time of second surgery to all-cause mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported quality of life, overall (QLQ-C30)</measure>
    <time_frame>15 months from inclusion</time_frame>
    <description>Evaluated by Eastern Cooperative Oncology Group Quality of Life Questionaire (QLQ-C30), a questionnaire developed to assess the quality of life of cancer patients. Scale 30 to 120 points, where higher is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported quality of life, brain specific(QLQ-BN20)</measure>
    <time_frame>15 months from inclusion</time_frame>
    <description>Evaluated by Eastern Cooperative Oncology Group Quality of Life Questionaire, Brain module (QLQ-BN20). The brain cancer module is meant for use among brain cancer patients varying in disease stage and treatment modality. Scale 20 to 80 points, where higher is worse.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with drugs based on functional profiling of autologous tumor cells in vitro</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Personalized drug combination</intervention_name>
    <description>A personalized drug combination will be prescribed to each patient based on the functional drug screen</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recurrence of histologically verified glioblastoma&#xD;
&#xD;
          -  Adequate biopsy to generate enough live cells to allow functional screening&#xD;
&#xD;
          -  Must be ambulatory with an Eastern Cooperative Oncology Group (ECOG) performance&#xD;
             status 0-1&#xD;
&#xD;
          -  Must be 15 to 70 years of age&#xD;
&#xD;
          -  Adequate bone marrow, liver and heart function&#xD;
&#xD;
          -  Must be competent to give consent&#xD;
&#xD;
          -  Signed informed consent and expected cooperation of the patients for the treatment and&#xD;
             follow up must be obtained and documented according to International Conference on&#xD;
             Harmonization Good Clinical Practice guidelines (ICH GCP), and national/local&#xD;
             regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients taking part in other clinical trials which could make inclusion or follow-up&#xD;
             difficult&#xD;
&#xD;
          -  Any reason why, in the opinion of the investigator, the patient should not participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einar O. Vik-Mo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Einar O. Vik-Mo, MD, PhD</last_name>
    <phone>23074343</phone>
    <phone_ext>+47</phone_ext>
    <email>uxvieb@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erlend Skaga, MD, PhD</last_name>
    <phone>23074915</phone>
    <phone_ext>+47</phone_ext>
    <email>erlend.skaga@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Einar O Vik-Mo, MD, PhD</last_name>
      <phone>+47 23074340</phone>
      <email>uxvieb@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Solveig Bringsli</last_name>
      <email>solbri@ous-hf.no</email>
    </contact_backup>
    <investigator>
      <last_name>Einar O. Vik-Mo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petter Brandal, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Skaga E, Kulesskiy E, Brynjulvsen M, Sandberg CJ, Potdar S, Langmoen IA, Laakso A, Gaál-Paavola E, Perola M, Wennerberg K, Vik-Mo EO. Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment. Clin Transl Med. 2019 Dec 30;8(1):33. doi: 10.1186/s40169-019-0253-6.</citation>
    <PMID>31889236</PMID>
  </reference>
  <reference>
    <citation>Skaga E, Kulesskiy E, Fayzullin A, Sandberg CJ, Potdar S, Kyttälä A, Langmoen IA, Laakso A, Gaál-Paavola E, Perola M, Wennerberg K, Vik-Mo EO. Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma. BMC Cancer. 2019 Jun 25;19(1):628. doi: 10.1186/s12885-019-5861-4.</citation>
    <PMID>31238897</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Einar Vik-Mo</investigator_full_name>
    <investigator_title>Head of Surgical Neuro-Oncology</investigator_title>
  </responsible_party>
  <keyword>functional screening</keyword>
  <keyword>personalized treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Anonymized data will regarding tumor characteristics and results of functional profiling will be made available after publishing.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

